These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23146787)

  • 1. Behavioral and intellectual functioning in patients with tyrosinemia type I.
    Pohorecka M; Biernacka M; Jakubowska-Winecka A; Biernacki M; Kuśmierska K; Kowalik A; Sykut-Cegielska J
    Pediatr Endocrinol Diabetes Metab; 2012; 18(3):96-100. PubMed ID: 23146787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?
    Daly A; Gokmen-Ozel H; MacDonald A; Preece MA; Davies P; Chakrapani A; McKiernan P
    J Hum Nutr Diet; 2012 Apr; 25(2):111-6. PubMed ID: 22168396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
    Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
    J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
    van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
    Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intellectual functioning in children with early shunted posthemorrhagic hydrocephalus.
    Lacy M; Pyykkonen BA; Hunter SJ; Do T; Oliveira M; Austria E; Mottlow D; Larson E; Frim D
    Pediatr Neurosurg; 2008; 44(5):376-81. PubMed ID: 18703883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emotional and behavioural functioning in children with tyrosinaemia type 1.
    Pohorecka M; Biernacki M; Jakubowska-Winecka A; Leszczynska-Iwanicka K; Rokicki D; Pokora P; Perkowska B; Pajdowska M; Biernacka M
    Pediatr Endocrinol Diabetes Metab; 2024; 30(1):8-13. PubMed ID: 39026474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosinaemia type II: an easily diagnosed metabolic disorder with a rewarding therapeutic response.
    al-Essa MA; Rashed MS; Ozand PT
    East Mediterr Health J; 1999 Nov; 5(6):1204-7. PubMed ID: 11924112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive functioning, behavior, and quality of life after stroke in childhood.
    Everts R; Pavlovic J; Kaufmann F; Uhlenberg B; Seidel U; Nedeltchev K; Perrig W; Steinlin M
    Child Neuropsychol; 2008 Jul; 14(4):323-38. PubMed ID: 18568780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting epilepsy-related cognitive problems in clinically referred children with epilepsy: is the WISC-IV a useful tool?
    Sherman EM; Brooks BL; Fay-McClymont TB; MacAllister WS
    Epilepsia; 2012 Jun; 53(6):1060-6. PubMed ID: 22554239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1.
    Lidzba K; Granström S; Lindenau J; Mautner VF
    Dev Med Child Neurol; 2012 Oct; 54(10):892-7. PubMed ID: 22881119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
    De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
    Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
    [No Abstract]   [Full Text] [Related]  

  • 12. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinic attenders with autism or attention-deficit/hyperactivity disorder: cognitive profile at school age and its relationship to preschool indicators of language delay.
    Hagberg BS; Miniscalco C; Gillberg C
    Res Dev Disabil; 2010; 31(1):1-8. PubMed ID: 19713073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Richner-Hanhart syndrome (tyrosinemia type II): a case report of delayed diagnosis with pseudodendritic corneal lesion.
    Iskeleli G; Bilgeç MD; Arici C; Atalay E; Oğreden T; Aydin A
    Turk J Pediatr; 2011; 53(6):692-4. PubMed ID: 22389994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies.
    Roizen N; Kasza K; Karrison T; Mets M; Noble AG; Boyer K; Swisher C; Meier P; Remington J; Jalbrzikowski J; McLeod R; Kipp M; Rabiah P; Chamot D; Estes R; Cezar S; Mack D; Pfiffner L; Stein M; Danis B; Patel D; Hopkins J; Holfels E; Stein L; Withers S; Cameron A; Perkins J; Heydemann P
    Pediatrics; 2006 Aug; 118(2):e379-90. PubMed ID: 16864640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartame, behavior, and cognitive function in children with attention deficit disorder.
    Shaywitz BA; Sullivan CM; Anderson GM; Gillespie SM; Sullivan B; Shaywitz SE
    Pediatrics; 1994 Jan; 93(1):70-5. PubMed ID: 7505423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Different verbal behavior in children with attention deficit between 7 and 12 years of age].
    Pineda DA; Restrepo MA; Henao GC; Gutiérrez-Clellen V; Sánchez D
    Rev Neurol; 1999 Dec 16-31; 29(12):1117-27. PubMed ID: 10652733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tyrosinemia type II. Case report].
    Benatiya AI; Bouayed MA; Touiza E; Daoudi K; Bhalil S; Elmesbahi I; Tahri H
    Bull Soc Belge Ophtalmol; 2005; (296):57-61. PubMed ID: 16050420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction.
    Seashore MR; Friedman E; Novelly RA; Bapat V
    Pediatrics; 1985 Feb; 75(2):226-32. PubMed ID: 3969322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.